Pharma Industry Pipeline Assessed by CBR Pharma Insights in Its In-demand Research Report Available at MarketPublishers.com
27 Jun 2017 • by Natalie Aster
LONDON – Innovation, specifically in new product development, is an important element of the pharma industry. The market is extremely research intensive, being highly dependent on a high degree of R&D investment and a robust product pipeline to sustain growth and ensure the generation of revenue in the long view. In case these is not successful innovation, defined broadly as the market launch of new therapeutic molecules for the cost-effective treatment or cure of illnesses, the industry is likely to face a considerable decline in revenue on a long-term horizon.
During the past decades, along with an upsurge in the number of novel molecular entity approvals by the FDA annually, the volume and proportion of these first-in-class approvals have gained traction as well. The percentage of first-in-class approvals has surged incessantly yearly since 1994, apart from the years 2005–2008, when the percentage was comparatively high.
In-demand research publication “Innovation and Clinical Trial Tracking Factbook 2017: An Assessment of the Pharmaceutical Pipeline” elaborated by CBR Pharma Insights offers an all-round, granular analysis of the 25,522 drug products that are presently in the pharma industry pipeline, from the stage of discovery up to pre-registration, and broken up into key indications and areas of medicine. The report benchmarks the pipeline against its size across each segment in comparison with 2015 and 2016, and offers an evaluation of the degree of first-in-class innovation. Furthermore, it offers a granular contextual analysis of the major drivers of this pipeline, alongside assessing the firms present in the pipeline and historical deal volumes and values. The report focuses on an insightful analysis of the innovative drug development, in particular, first-in-class innovation.
More in-demand research studies by the publisher can be found at CBR Pharma Insights page.